---
company: Covista Inc.
ticker: CVSA
form: 8-K
filed: 2026-10-29
accepted: 2026-10-29T20:16:28+00:00
accession: 0000730464-26-000062
source: https://www.sec.gov/Archives/edgar/data/730464/000073046426000062/
quarterly_report: https://www.sec.gov/Archives/edgar/data/730464/000110465926120213/
---

# Covista (CVSA) Q1 2027 earnings

## Header

- Company: Covista Inc.
- Reported: 2026-10-29 16:16 AMC ET
- Source: 8-K only — accession 0000730464-26-000062, Item 2.02 + Exhibit 99.1
- Verdict: Revenue and adjusted EPS growth accelerated in the first quarter of FY2027, and management raised guidance for the full year.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---:|---:|---|---|
| Revenue | $511.5M | +10.7% | — | Ex. 99.1, income statement |
| EPS (GAAP) | $1.95 | +16.8% | — | Ex. 99.1, income statement |
| EPS (adjusted) | $2.19 | +25.1% | — | Ex. 99.1, income statement |
| Adj. EBITDA | $540.9M | +9.0% | — | Ex. 99.1, income statement |

## Revenue breakdown

| Segment | Actual | YoY | Share of revenue | Note |
|---|---:|---:|---:|---|
| Chamberlain | $192.4M | +7.4% | 37.6% | Total students +1.3% YoY |
| Walden | $216.7M | +14.1% | 42.4% | Total students +12.8% YoY |
| Medical and Veterinary | $102.5M | +10.0% | 20.0% | Total students +3.5% YoY |

## Margins and costs

- Gross margin: not stated in the 8-K
- Operating expenses: Operating cost and expense $413.5M (+9.7% YoY)
- One-offs in the quarter: Restructuring expense $163k; Strategic advisory costs $6.2M; Debt modification costs $756k
- Effective tax rate: 31.0% (FY27 YTD)
- Non-GAAP bridge: Adds back restructuring, amortization, strategic advisory costs, debt modification costs, and a U.S. tax benefit from foreign-derived income

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---:|---|
| Total enrollment | 104,713 | — | 97,260 | +7.6% YoY |
| Free cash flow | $355.2M | $393.1M | — | -9.6% vs prior quarter |
| Net leverage | 0.5x | 0.5x | — | Stable |

## Guidance

| Metric | Guide | Prior guide | Change |
|---|---:|---:|---|
| Revenue | $2,060M - $2,095M | $2,050M - $2,090M | +$10M range |
| Adjusted EPS | $9.00 - $9.20 | $8.90 - $9.15 | +$0.10 range |

## What drove it

- Revenue story: Revenue grew 10.7% YoY, driven by double-digit growth in Walden (+14.1%) and Medical and Veterinary (+10.0%), with Chamberlain growing 7.4%.
- EPS story: Adjusted EPS grew 25.1% YoY, supported by revenue growth, operating leverage, and a U.S. tax benefit from foreign-derived income.
- One-off check: Strategic advisory costs increased to $6.2M from $1.7M YoY; restructuring expense decreased to $163k from $310k YoY.

## The good

- Revenue growth accelerated to 10.7% YoY
- Adjusted EPS grew 25.1% YoY
- Management raised FY2027 revenue and adjusted EPS guidance

## The bad

- Operating margin (GAAP) declined to 19.2% from 18.5% YoY
- Free cash flow decreased 9.6% vs the prior quarter

## The ugly

- none

## Open questions

- What is the impact of the CFO's planned retirement on capital allocation or strategy execution?
- What specific drivers caused the decline in GAAP operating margin despite revenue growth?

## Full release

### Earnings: CVSA — filed 2026-10-29

Covista Inc. (CVSA) · Form 8-K, Item 2.02 · Filed 2026-10-29 · [SEC filing](https://www.sec.gov/Archives/edgar/data/730464/000073046426000062/)

Investor Contact:

Jeremy Cohen

Investor.Relations@Covista.com

​

Media Contact:

Nick Lucido

CovistaMedia@Covista.com

Covista Reports First Quarter Fiscal Year 2027 Results; Raises Fiscal Year 2027 Revenue and Adjusted EPS Guidance

Total enrollment up 7.6% YoY

Revenue up 10.7% YoY

Diluted earnings per share $1.95; Adjusted EPS $2.19, growth of 25.1% YoY

Chief Financial Officer Robert Phelan announces planned retirement; will continue to serve until a successor is named

First quarter highlights

Capital allocation

Increased fiscal year 2027 guidance

​

​

CHICAGO – October 29, 2026 – Covista Inc. (NYSE: CVSA), America’s largest healthcare educator, today reported first quarter fiscal year 2027 results (ended Sep. 30, 2026). This quarter, the Company launched

Purpose at Scale, its three-year strategy to train the next generation of healthcare professionals at industry-leading scale.

Purpose at Scale is underpinned by operational excellence, platform extension, employer integration and a technology focus.

“

Purpose at Scale is delivering and all four pillars of the strategy are contributing to our momentum. Total enrollment grew for the 13th consecutive quarter, powering our double-digit revenue growth and continued margin expansion. On that strength, we are raising our fiscal 2027 guidance,” said Steve Beard, Chairman and Chief Executive Officer, Covista. “The demand behind our strategy is durable, and Covista is critical infrastructure for American healthcare. We serve an urgent need in the communities where care matters most, and by doing that well, we are strategically positioned to create lasting value for our shareholders.”

Financial Highlights

Selected financial data for the three months ended Sep. 30, 2026:

​

Business Highlights

Segment Highlights

Chamberlain

​

​

Walden

​

​

Medical and Veterinary

​

​

Fiscal Year 2027 Outlook

Covista raised its revenue guidance for fiscal year 2027 from a range of $2,050 million to $2,090 million, or approximately 5% to 7% growth year-over-year, to a range of $2,060 million to $2,095 million, or approximately 5.5% to 7% growth year-over-year.

Covista also raised its adjusted earnings per share guidance from a range of $8.90 to $9.15, or approximately 8% to 11% growth year-over-year, to a range of $9.00 to $9.20, or approximately 9% to 11.5% growth year-over-year.

Management Update

Chief Financial Officer Robert Phelan has decided to retire from Covista after nearly seven years, as part of a planned transition. He will remain in this role until a successor is named, with no change in responsibilities. He will support the incoming Chief Financial Officer through a transition period. An active search is underway.

Conference Call and Webcast Information

Covista will hold a conference call to discuss its first quarter fiscal year 2027 results today at 4:00 p.m. CT (5:00 p.m. ET).

The call can be accessed by dialing +1 877-407-6184 (U.S. participants) or +1 201-389-0877 (international participants) and stating “Covista earnings call” or by using conference ID:13762351. The call will be simulcast through the Covista investor relations website at: https://investors.covista.com.

Covista will archive a replay of the call for 30 days. To access the replay, dial +1 877-660-6853 (U.S.) or +1 201-612-7415 (international), conference ID: 13762351, or visit the Covista investor relations website.

About Covista

Covista (NYSE: CVSA) is America's largest healthcare educator, serving 100,000 students and supported by a community of 400,000 alumni across five accredited institutions. Through personalized, tech-enabled education powered by 10,000 faculty and colleagues, Covista expands access to healthcare careers and addresses the U.S. healthcare workforce shortage at scale. Covista is the parent company of American University of the Caribbean School of Medicine, Chamberlain University, Ross University School of Medicine, Ross University School of Veterinary Medicine and Walden University. For more information, visit covista.com and follow us on

LinkedIn,

Instagram and

YouTube.

​

Cautionary Disclosure Regarding Forward-Looking Statements

Certain statements contained in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, which includes statements regarding Covista’s future growth. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “future,” “believe,” “project,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “may,” “will,” “would,” “could,” “can,” “continue,” “preliminary,” “potential,” “range,” and similar terms. These forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those described in the statements. Important factors that could cause actual results to differ materially from the expectations expressed or implied by our forward-looking statements are disclosed in Item 1A. “Risk Factors,” of our Annual Report on Form 10-K. You should evaluate forward-looking statements in the context of these risks and uncertainties and are cautioned to not place undue reliance on such forward-looking statements. We caution you that these factors may not contain all of the factors that are important to you. We cannot assure you that we will realize the results, performance or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. All forward-looking statements are based on information available to us as of the date any such statements are made, and Covista assumes no obligation to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized, except as required by law.

​

A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of special items that may be incurred in the future, although these special items could be material to Covista's results in accordance with GAAP.

###

​

​

Covista Inc.

Consolidated Balance Sheets

(unaudited)

(in thousands)

​

​

​

​

Covista Inc.

Consolidated Statements of Income

(unaudited)

(in thousands, except per share data)

​

​

​

​

​

Covista Inc.

Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

​

​

​

​

​

Covista Inc.

Segment Revenue

(unaudited)

(in thousands)

​

​

Covista Inc.

Non-GAAP Financial Measures and Reconciliations

We believe that certain non-GAAP financial measures provide investors with useful supplemental information regarding the underlying business trends and performance of Covista’s ongoing operations as seen through the eyes of management and are useful for period-over-period comparisons. We use these supplemental non-GAAP financial measures internally in our assessment of performance and budgeting process. However, these non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. The following are non-GAAP financial measures used in the subsequent GAAP to non-GAAP reconciliation tables:

Adjusted net income (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, debt modification costs, U.S. tax benefit due to an increase in foreign-derived income, and loss (income) from discontinued operations.

Adjusted earnings per share (most comparable GAAP measure: diluted earnings per share) – Measure of Covista’s diluted earnings per share adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, loss on debt extinguishment, debt modification costs, U.S. tax benefit due to an increase in foreign-derived income, and loss (income) from discontinued operations.

Adjusted operating income (most comparable GAAP measure: operating income) – Measure of Covista’s operating income adjusted for restructuring expense, amortization of acquired intangible assets, strategic advisory costs, and debt modification costs.

Adjusted EBITDA (most comparable GAAP measure: net income) – Measure of Covista’s net income adjusted for loss (income) from discontinued operations, interest expense, other income, net, provision for income taxes, depreciation, amortization of acquired intangible assets, amortization of cloud computing implementation assets, stock-based compensation, restructuring expense, strategic advisory costs, and debt modification costs. Provision for income taxes, interest expense, and other income, net are not recorded at the reportable segments, and therefore, the segment adjusted EBITDA reconciliations begin with adjusted operating income.

Free cash flow (most comparable GAAP measure: net cash provided by operating activities-continuing operations) – Defined as net cash provided by operating activities-continuing operations less capital expenditures.

Net debt – Defined as total long-term debt principal less cash and cash equivalents.

Net leverage – Defined as net debt divided by adjusted EBITDA.

A description of special items in our non-GAAP financial measures described above are as follows:

Covista Inc.

Adjusted Operating Income

(unaudited)

(in thousands)

​

(1)

Consolidated results include Home Office activities not allocated to segments.

​

Covista Inc.

Adjusted EBITDA

(unaudited)

(in thousands)

​

(1)

Consolidated results include Home Office activities not allocated to segments.

Covista Inc.

Adjusted Earnings

(unaudited)

(in thousands, except per share data)

​

​

Note: May not sum due to rounding.

​

Covista Inc.

Free Cash Flow

(unaudited)

(in thousands)

​

​

​

​

Covista Inc.

Net Leverage

(unaudited)

(in thousands)

​

​

#### Financial statements

##### Income Statement (Three Months Ended — Chamberlain (in millions))

| | Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | Three Months Ended – September 30, – % Change |
|---|---:|---:|---:|
| Revenue | 192.4 | 179.2 | 7.4% |
| Operating Income | 26.7 | 25.6 | 4.4% |
| Adj. Operating Income | 26.7 | 25.6 | 4.4% |
| Adj. EBITDA | 37.6 | 35.1 | 7.1% |
| Total Students(2) | 40,351 | 39,846 | 1.3% |

##### Income Statement (Three Months Ended — Walden (in millions))

| | Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | Three Months Ended – September 30, – % Change |
|---|---:|---:|---:|
| Revenue | 216.7 | 190 | 14.1% |
| Operating Income | 63.6 | 53.3 | 19.5% |
| Adj. Operating Income | 65 | 56.1 | 16.0% |
| Adj. EBITDA | 71.9 | 61.9 | 16.1% |
| Total Students(2) | 58,881 | 52,216 | 12.8% |

##### Income Statement (Three Months Ended — Medical and Veterinary (in millions))

| | Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | Three Months Ended – September 30, – % Change |
|---|---:|---:|---:|
| Revenue | 102.5 | 93.1 | 10.0% |
| Operating Income | 22.3 | 16.7 | 33.0% |
| Adj. Operating Income | 22.3 | 16.8 | 32.7% |
| Adj. EBITDA | 27.4 | 21.4 | 27.9% |
| Total Students(2) | 5,481 | 5,297 | 3.5% |

##### Income Statement (Three Months Ended — (in thousands, except per share data))

| | Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 |
|---|---:|---:|
| Revenue | 511,534 | 462,288 |
| **Operating cost and expense:** | | |
| Cost of educational services | 220,759 | 200,767 |
| Student services and administrative expense | 192,585 | 175,734 |
| Restructuring expense | 163 | 310 |
| Total operating cost and expense | 413,507 | 376,811 |
| Operating income | 98,027 | 85,477 |
| Interest expense | -9,944 | -11,090 |
| Other income, net | 1,416 | 2,486 |
| Income from continuing operations before income taxes | 89,499 | 76,873 |
| Provision for income taxes | -18,017 | -15,811 |
| Income from continuing operations | 71,482 | 61,062 |
| **Discontinued operations:** | | |
| (Loss) income from discontinued operations before income taxes | -5,420 | 747 |
| Benefit from income taxes | 1,365 | 23 |
| (Loss) income from discontinued operations | -4,055 | 770 |
| Net income and comprehensive income | 67,427 | 61,832 |
| **Basic:** | | |
| Continuing operations | 2.11 | 1.69 |
| Discontinued operations | -0.12 | 0.02 |
| Total basic earnings per share | 1.99 | 1.71 |
| **Diluted:** | | |
| Continuing operations | 2.07 | 1.65 |
| Discontinued operations | -0.12 | 0.02 |
| Total diluted earnings per share | 1.95 | 1.67 |
| **Weighted-average shares outstanding:** | | |
| Basic shares | 33,951 | 36,111 |
| Diluted shares | 34,573 | 37,057 |

##### Income Statement (Three Months Ended — (in thousands))

| | Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | Three Months Ended – September 30, – Increase/(Decrease) – $$ | Three Months Ended – September 30, – Increase/(Decrease) – % |
|---|---:|---:|---:|---:|
| **Chamberlain:** | | | | |
| Operating income | 26,730 | 25,608 | 1,122 | 4.4% |
| Adjusted operating income | 26,730 | 25,608 | 1,122 | 4.4% |
| Operating margin | 13.9% | 14.3% |  |  |
| Adjusted operating margin | 13.9% | 14.3% |  |  |
| **Walden:** | | | | |
| Operating income | 63,649 | 53,269 | 10,380 | 19.5% |
| Amortization of acquired intangible assets | 1,394 | 2,805 | -1,411 |  |
| Adjusted operating income | 65,043 | 56,074 | 8,969 | 16.0% |
| Operating margin | 29.4% | 28.0% |  |  |
| Adjusted operating margin | 30.0% | 29.5% |  |  |
| **Medical and Veterinary:** | | | | |
| Operating income | 22,251 | 16,728 | 5,523 | 33.0% |
| Restructuring expense |  | 44 | -44 |  |
| Adjusted operating income | 22,251 | 16,772 | 5,479 | 32.7% |
| Operating margin | 21.7% | 18.0% |  |  |
| Adjusted operating margin | 21.7% | 18.0% |  |  |
| **Covista(1):** | | | | |
| Operating income (GAAP) | 98,027 | 85,477 | 12,550 | 14.7% |
| Restructuring expense | 163 | 310 | -147 |  |
| Amortization of acquired intangible assets | 1,394 | 2,805 | -1,411 |  |
| Strategic advisory costs | 6,231 | 1,684 | 4,547 |  |
| Debt modification costs | 756 |  | 756 |  |
| Adjusted operating income (non-GAAP) | 106,571 | 90,276 | 16,295 | 18.1% |
| Operating margin (GAAP) | 19.2% | 18.5% |  |  |
| Adjusted operating margin (non-GAAP) | 20.8% | 19.5% |  |  |

##### Income Statement (Three Months Ended — (in thousands))

| | Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | Three Months Ended – September 30, – Increase/(Decrease) – $$ | Three Months Ended – September 30, – Increase/(Decrease) – % |
|---|---:|---:|---:|---:|
| **Chamberlain:** | | | | |
| Adjusted operating income (GAAP) | 26,730 | 25,608 | 1,122 | 4.4% |
| Depreciation | 6,094 | 5,375 | 719 |  |
| Amortization of cloud computing implementation assets | 2,386 | 1,527 | 859 |  |
| Stock-based compensation | 2,372 | 2,570 | -198 |  |
| Adjusted EBITDA (non-GAAP) | 37,582 | 35,080 | 2,502 | 7.1% |
| Adjusted EBITDA margin (non-GAAP) | 19.5% | 19.6% |  |  |
| **Walden:** | | | | |
| Adjusted operating income (GAAP) | 65,043 | 56,074 | 8,969 | 16.0% |
| Depreciation | 1,784 | 1,940 | -156 |  |
| Amortization of cloud computing implementation assets | 2,253 | 1,204 | 1,049 |  |
| Stock-based compensation | 2,782 | 2,653 | 129 |  |
| Adjusted EBITDA (non-GAAP) | 71,862 | 61,871 | 9,991 | 16.1% |
| Adjusted EBITDA margin (non-GAAP) | 33.2% | 32.6% |  |  |
| **Medical and Veterinary:** | | | | |
| Adjusted operating income (GAAP) | 22,251 | 16,772 | 5,479 | 32.7% |

##### Income Statement (Three Months Ended — (in thousands, except per share data))

| | Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 |
|---|---:|---:|
| Diluted earnings per share (GAAP) | 1.95 | 1.67 |
| **Effect on diluted earnings per share:** | | |
| Restructuring expense | 0 | 0.01 |
| Amortization of acquired intangible assets | 0.04 | 0.08 |
| Strategic advisory costs | 0.18 | 0.05 |
| Loss on debt extinguishment and debt modification costs | 0.02 | 0.01 |
| U.S. tax benefit due to an increase in foreign-derived income | -0.06 |  |
| Income tax impact on non-GAAP adjustments(1) | -0.06 | -0.03 |
| Loss (income) from discontinued operations | 0.12 | -0.02 |
| Adjusted earnings per share (non-GAAP) | 2.19 | 1.75 |
| Diluted shares | 34,573 | 37,057 |

##### Income Statement (Twelve Months Ended — (in thousands))

| | Twelve Months Ended – September 30, 2026 | September 30, 2026 |
|---|---:|---:|
| **Covista:** | | |
| Net income (GAAP) | 257,161 |  |
| Loss from discontinued operations | 20,634 |  |
| Interest expense | 44,289 |  |
| Other income, net | -6,108 |  |
| Provision for income taxes | 79,950 |  |
| Depreciation and amortization | 73,836 |  |
| Stock-based compensation | 41,104 |  |
| Restructuring expense | 6,182 |  |
| Strategic advisory costs | 23,109 |  |
| Debt modification costs | 756 |  |
| Adjusted EBITDA (non-GAAP) | 540,913 |  |
| Total long-term debt principal |  | 510,000 |
| Less: Cash and cash equivalents |  | -222,223 |
| Net debt (non-GAAP) |  | 287,777 |
| Net leverage (non-GAAP) |  | 0.5x |

##### Balance Sheet (September 30, — (in thousands))

| | September 30, – 2026 | June 30, – 2026 |
|---|---:|---:|
| **Current assets:** | | |
| Cash and cash equivalents | 222,223 | 406,316 |
| Restricted cash | 2,336 | 1,438 |
| Accounts and financing receivables, net | 241,469 | 169,561 |
| Prepaid expenses and other current assets | 86,542 | 75,126 |
| Total current assets | 552,570 | 652,441 |
| **Noncurrent assets:** | | |
| Property and equipment, net | 324,706 | 302,649 |
| Operating lease assets | 197,511 | 204,364 |
| Intangible assets, net | 752,860 | 754,254 |
| Goodwill | 961,262 | 961,262 |
| Other assets, net | 139,364 | 137,738 |
| Total noncurrent assets | 2,375,703 | 2,360,267 |
| Total assets | 2,928,273 | 3,012,708 |
| **Current liabilities:** | | |
| Accounts payable | 96,383 | 124,763 |
| Accrued payroll and benefits | 57,720 | 78,669 |
| Accrued liabilities | 126,214 | 94,364 |
| Deferred revenue | 365,096 | 259,125 |
| Current operating lease liabilities | 33,984 | 34,799 |
| Current portion of long-term debt | 5,100 | 5,100 |
| Total current liabilities | 684,497 | 596,820 |
| **Noncurrent liabilities:** | | |
| Long-term debt | 495,131 | 657,750 |
| Long-term operating lease liabilities | 219,374 | 207,846 |
| Deferred income taxes | 69,320 | 61,782 |
| Other liabilities | 38,308 | 42,325 |
| Total noncurrent liabilities | 822,133 | 969,703 |
| Total liabilities | 1,506,630 | 1,566,523 |
| **Commitments and contingencies** | | |
| Total shareholders' equity | 1,421,643 | 1,446,185 |
| Total liabilities and shareholders' equity | 2,928,273 | 3,012,708 |

##### Cash Flow (Three Months Ended — (in thousands))

| | Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 |
|---|---:|---:|
| **Operating activities:** | | |
| Net income | 67,427 | 61,832 |
| Loss (income) from discontinued operations | 4,055 | -770 |
| Income from continuing operations | 71,482 | 61,062 |
| **Adjustments to reconcile net income to net cash provided by operating activities:** | | |
| Stock-based compensation | 8,181 | 8,293 |
| Amortization of operating lease assets | 7,018 | 7,216 |
| Depreciation | 10,862 | 10,296 |
| Amortization of acquired intangible assets | 1,394 | 2,805 |

##### Cash Flow (Twelve Months Ended — (in thousands))

| | Twelve Months Ended – FY26 – Q1 | Twelve Months Ended – FY26 – Q2 | Twelve Months Ended – FY26 – Q3 | Twelve Months Ended – FY26 – Q4 | Twelve Months Ended – FY27 – Q1 |
|---|---:|---:|---:|---:|---:|
| Net cash provided by operating activities-continuing operations (GAAP) | 374,796 | 427,890 | 406,335 | 470,796 | 454,438 |
| Capital expenditures | -55,936 | -59,880 | -69,872 | -77,696 | -99,265 |
| Free cash flow (non-GAAP) | 318,860 | 368,010 | 336,463 | 393,100 | 355,173 |
